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Abstract: BACKGROUND Headache is a frequent symptom following COVID-19 immunization with
a typical onset within days post-vaccination. Cases of cerebral venous thrombosis (CVT) have been
reported in adenovirus vector-based COVID-19 vaccine recipients. FINDINGS We reviewed all vaccine
related CVT published cases by April 30, 2021. We assessed demographic, clinical variables and the
interval between the vaccination and onset of headache. We assessed whether the presence of headache
was associated with higher probability of death or intracranial hemorrhage. We identified 77 cases of CVT
after COVID-19 vaccination. Patients’ age was below 60 years in 74/77 (95.8%) cases and 61/68 (89.7%)
were women. Headache was described in 38/77 (49.4%) cases, and in 35/38 (92.1%) was associated with
other symptoms. Multiple organ thrombosis was reported in 19/77 (24.7%) cases, intracranial hemorrhage
in 33/77 (42.9%) cases and 19/77 (24.7%) patients died. The median time between vaccination and CVT-
related headache onset was 8 (interquartile range 7.0-9.7) days. The presence of headache was associated
with a higher odd of intracranial hemorrhage (OR 7.4; 95% CI: 2.7-20.8, p < 0.001), but not with
death (OR: 0.51, 95% CI: 0.18-1.47, p = 0.213). CONCLUSION Delayed onset of headache following
an adenovirus vector-based COVID-19 vaccine is associated with development of CVT. Patients with
new-onset headache, 1 week after vaccination with an adenovirus vector-based vaccine, should receive a
thorough clinical evaluation and CVT must be ruled out.
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Abstract
Background: Headache is a frequent symptom following COVID-19 immunization with a typical onset within days
post-vaccination. Cases of cerebral venous thrombosis (CVT) have been reported in adenovirus vector-based COVID-
19 vaccine recipients.
Findings: We reviewed all vaccine related CVT published cases by April 30, 2021. We assessed demographic, clinical
variables and the interval between the vaccination and onset of headache. We assessed whether the presence of
headache was associated with higher probability of death or intracranial hemorrhage.
We identified 77 cases of CVT after COVID-19 vaccination. Patients’ age was below 60 years in 74/77 (95.8%) cases and
61/68 (89.7%) were women. Headache was described in 38/77 (49.4%) cases, and in 35/38 (92.1%) was associated with
other symptoms. Multiple organ thrombosis was reported in 19/77 (24.7%) cases, intracranial hemorrhage in 33/77
(42.9%) cases and 19/77 (24.7%) patients died. The median time between vaccination and CVT-related headache onset
was 8 (interquartile range 7.0–9.7) days. The presence of headache was associated with a higher odd of intracranial
hemorrhage (OR 7.4; 95% CI: 2.7–20.8, p < 0.001), but not with death (OR: 0.51, 95% CI: 0.18–1.47, p = 0.213).
Conclusion: Delayed onset of headache following an adenovirus vector-based COVID-19 vaccine is associated with
development of CVT. Patients with new-onset headache, 1 week after vaccination with an adenovirus vector-based
vaccine, should receive a thorough clinical evaluation and CVT must be ruled out.
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Introduction
Headache is within the most frequent adverse effects
following coronavirus disease 2019 (COVID-19)
immunization. It is reported by approximately half of
the vaccine recipients, both in clinical trials and real-
world data [1, 2]. Headache typically presents within the
first 72 h post-vaccination and may be associated with
additional symptoms, such as fatigue, fever, myalgia,
arthralgia, or diarrhea [1, 2].
Several cases of cerebral venous thrombosis (CVT)
have been reported in non-replicant adenovirus vector-
based COVID-19 vaccine recipients (Oxford-AstraZe-
neca ChAdOx1-S and Johnson & Johnson (J&J) Janssen
Ad26.COV2S) [3–7]. The association was based on the
presence of thrombocytopenia [3–8], anti-platelet factor
4 antibodies [6, 7], and multiple organ thrombosis (vac-
cine-induced immune thrombotic thrombocytopenia
(VITT)) [3–8]. There was a higher mortality rate [3–8]
than in other CVT series reported in the literature and
an increased standardized morbidity ratio (SMR) in pa-
tients aged between 30 and 49 [3]. SMR is also known as
observed-to-expected analysis, which analyses the ratio
between the observed number of cases in the population
over the number of cases that would be expected based
on the baseline incidence according to databases and
prior studies [9, 10].
Headache is the most frequent symptom in CVT, and it
may occur isolated or accompanied by other symptoms
[9–11]. As in other secondary headache disorders, CVT
may be recognized by the presence of red flags [11, 12].
Herein we highlight a potential novel red flag based on
the available scientific data that may help clinicians to
properly identify cases of CVT following non-replicant
adenovirus vector-based COVID-19 vaccines.
Methods
This is an observational study with case-control design.
The study population were vaccinated with non-
replicant adenovirus vector-based vaccines. The case
definition was CVT following COVID-19 non-replicant
adenovirus vector-based vaccines. We screened PubMed
for all published cases and case series between March 01
and April 30, 2021, and assessed specific reports from
the United States Centers for Disease Control and Pre-
vention and the European Medicines Agency providing
patient-level data. The search term is available in the
supplementary appendix. We assessed and extracted the
following variables, which are presented as descriptive
statistics: age, sex, use of contraceptives or hormone-
replacement therapy, presence of headache, presence of
additional symptoms, the interval between the vaccin-
ation and the first symptom, intracranial hemorrhage,
and death. We compared the time elapsed between
vaccination and the first clinical onset in patients with
and without headache. As control group, we reviewed
the United States Vaccine Adverse Event Reporting
System (VAERS) [2] reports under the symptom “head-
ache” following COVID-19 vaccination up to April 30,
2021, assessing the number of days between the
immunization and the headache onset. In the statistical
analysis, we assessed whether the presence of headache
in patients with CVT was associated with higher prob-
ability of death or with higher probability of intracranial
hemorrhage by univariate logistic regression, presented
as odds ratio (OR) and 95% confidence interval (CI).
The statistical signification threshold was 0.05 and statis-
tical tests were two-tailed. No statistical power calcula-
tion was conducted prior to the study. Statistical analysis
was done with SPSS version 26.0.
Results
We identified 77 cases of CVT included in eight publica-
tions (supplementary appendix). Patients’ age was avail-
able in 71 cases, and was below 40 in 46.5%, below 60 in
95.8% and between 60 and 69 years in 4.2% cases. The
majority of cases 61/68 (89.7%) were women. Five (5.2%)
patients used contraceptives and one (1.3%) received
estrogen therapy.
The median time between the vaccination and the
first symptom was 8 days (inter-quartile range (IQR)
7–12, range 1–19, n = 70). The presence of headache
was described in 38/77 cases (49.4%). In 35/38
patients (92.1%), it was associated with other systemic
or neurological symptoms. The CVT-related clinical
symptoms started earlier in patients with headache
(median 8, IQR 7–9.7, range 2–15) than in patients
without headache (median 10, IQR 7–12.2, range 1–
19), (P = 0.037, Mann-Whitney test). Figure 1 shows
the days elapsed between vaccination and headache
onset. Intracranial hemorrhage was present in 33/77
(42.9%) cases, multiple location thrombosis was re-
ported in 19/77 (24.7%) cases, and 19/77 (24.7%) died.
In patients with CVT, the presence of headache was
associated with the presence of intracranial
hemorrhage (odds ratio (OR) 7.45; 95% confidence
interval (CI): 2.67–20.80, P < 0.001), but not with a
higher odd of death (OR: 0.51, 95% CI: 0.18–1.47,
P = 0.213).
Discussion
Although headache is a common symptom after vaccin-
ation, it typically presents and resolves within the same
day or a few days later [1, 2]. CVT, and other thrombotic
complications in adenovirus-based vaccine recipients
share a unique feature, the delayed presentation. In most
of the reported cases symptoms started 1 week after
immunization. Headache was not described in detail in
most cases, but in the few it was, it was reported as
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severe, progressive and treatment-resistant, all of them
well-known red flags [ 12].
Diagnostic delay is common in CVT [9]. Prompt treat-
ment likely improves the clinical outcome, and therefore,
every physician must be aware of the potential risk of vac-
cine related thrombotic complications. Given this know-
ledge and the possibility of vaccine-related CVT, patients
with new-onset headache, 1 week after immunization,
should receive a thorough clinical evaluation and be
closely monitored. Non-contrast.
computed tomography (CT) may detect indirect find-
ings of CVT, including hyperdense vein or sinus (cord
sign), venous infarcts, brain oedema and intracranial
hemorrhages; however, the optimal imaging test in case
of suspicion are contrast brain CT with CT venogram,
magnetic resonance imaging (MRI) with contrast and/or
venogram, showing a filling defect in a venous sinus
(empty delta sign) [10, 13].
The pathophysiology of thrombosis with thrombocytopenia
syndrome has been recently discussed [7, 14, 15]. The
role of anti-platelet factor-4 antibodies seem causa-
tive, inducing platelet activation, aggregation, and
thrombosis, leading to a severe platelet consumption
and thrombocytopenia. According to the existing evi-
dence, an interim guideline published by the World
Health Organization (WHO) states that the treatment
should include the treatment of the immune-mediated
phenomenon and adequate anticoagulation according to
the existing evidence [14]. For the first, intravenous
immunoglobulins seem to be the preferred option, while
as anticoagulants, non-heparin-based anticoagulants must
be used, while heparin-based anticoagulants and platelet
infusion should be avoided [14].
Conclusion
To conclude, delayed onset of headache following an
adenovirus vector-based COVID-19 vaccine is associated
with CVT. Patients with new-onset headache, 1 week
after vaccination with an adenovirus vector-based vac-
cine, should receive a thorough clinical evaluation and
CVT must be considered in the diagnostic work-up.
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Fig. 1 Temporal distribution of vaccine-related headache in the general population and vaccine-related cerebral venous sinus thrombosis
headache. Orange bars represent the proportion of patients that present headache during each day after vaccination according to VAERS data2.
Blue bars represent the proportion of patients with headache attributed to vaccine-related cerebral venous sinus thrombosis
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